Whalesbook
KKR ka support aur brokerage ka 'BUY' call, HCG mein dikhi tezi!
HealthCare Global Enterprises (HCG) ke liye sab kuch positive lag raha hai! Pichle quarter mein 18% ka zabardast EBITDA growth aur KKR ka strategic investment logon ka confidence badha raha hai. Prabhudas Lilladher ne is stock ko 'BUY' bola hai aur ₹820 ka target price diya hai. Ye sab isliye kyunki company operational efficiency aur margins ko improve karne par focus kar rahi hai. Haalanki HCG ke current margins 14% ke aas-paas hain, jo industry average se kam hai, par brokerage ko lagta hai KKR ke aane se sab theek ho jayega.
KKR ke investment se margins mein aur sudhaar ka chance!
Prabhudas Lilladher ne HealthCare Global Enterprises (HCG) ko 'BUY' rating di hai aur ₹820 ka target set kiya hai. Is positive outlook ka main reason hai HCG ka Q4 mein 18% year-on-year consolidated EBITDA growth, jo ₹1.25 billion tak pahunch gaya. Brokerage ne HCG ke asset-light strategy ko bhi highlight kiya hai, jismein company partnerships ka use karke capital-efficient business bana rahi hai. KKR ke recent investment aur low-margin fertility business ko bechne se operational aur financial efficiency mein kaafi sudhaar hone ki ummeed hai. Agar HCG ke current margins 14% industry peers se piche hain, toh Prabhudas Lilladher ko lagta hai ki KKR ke involvement se growth aur tezi se hogi. Ye growth beds badhane, payor mix ko improve karne aur targeted marketing se aa sakti hai, jisse margins ko boost milega. Firm ne FY26 se FY28 tak EBITDA CAGR 23% rehne ka estimate lagaya hai. Filhaal, HCG 19 times EV/EBITDA par trade kar raha hai. ₹820 ka target price 22 times FY28E EV/EBITDA ke hisab se hai. Poore FY26 ke liye, company ne 15% revenue growth (₹2,545 crore) aur 19% adjusted EBITDA mein badhotri (₹471 crore) report ki hai.
Valuation aur competitors ka comparison
HealthCare Global Enterprises (HCG) ka P/E ratio filhaal 387.11 hai, jo sector average 55.69 se kaafi zyada hai. Iske competitors jaise Apollo Hospitals Enterprises Ltd. aur Fortis Healthcare Ltd. ka P/E 63.83 aur 75.26 hai. Is high P/E ke bawajood, analysts HCG ko 'Strong Buy' rating de rahe hain, aur ₹753.50 ka average target price de rahe hain, jo 18% se zyada ka upside potential dikhata hai. Ye positive view is forecast par bhi based hai ki agle teen saal mein revenue 18% CAGR se grow karega. KKR ne February 2025 mein $400 million mein controlling stake acquire kiya hai, jo ek bada development hai. KKR ne Max Healthcare mein bhi operational improvements karke value create ki hai. KKR ka focus operational enhancements, cost management, aur strategic expansion par hai, jo HCG ke goals se match karta hai. Lekin, HCG ki projected revenue growth 13% hai, jo Indian Healthcare industry ke 17% forecast se thodi kam hai.
Margin gaps aur valuation par chinta
Brokerage report mein margin expansion ki baat ki gayi hai, par HCG ke current pre-IND AS margins 14% ke aas-paas hain, jo industry peers se kam hain. Better margins ke liye KKR dwara significant operational improvements ki zarurat hogi. Company ka P/E ratio 387.11 apne peers aur sector ke comparison mein kaafi high hai. Apollo Hospitals aur Fortis Healthcare jaise stocks 63.83 aur 75.26 ke P/E par trade kar rahe hain. EBITDA CAGR 23% se grow hone ke baad bhi, current valuation stretched lag raha hai. HCG ka return on equity (ROE) bhi last three years mein 4.25% raha hai. Promoter holding bhi last three years mein kam hui hai. 'Strong Buy' rating ke bawajood, margin difference aur high valuation metrics ko dhyan mein rakhte hue cautious rehna hoga. Company ko projected growth aur margin improvement targets achieve karne honge taaki current stock price aur ₹820 ka target justify ho sake.